These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3785144

  • 21. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
    Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P.
    Biochem J; 1988 Aug 15; 254(1):239-44. PubMed ID: 3140797
    [Abstract] [Full Text] [Related]

  • 22. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity.
    Douvas GS, May MH, Kolnagou A, Kontoghiorghes GJ.
    Arzneimittelforschung; 2002 Aug 15; 52(1):45-52. PubMed ID: 11838274
    [Abstract] [Full Text] [Related]

  • 23. Effects of hydroxypyridinone iron chelators in combination with antimalarial drugs on the in vitro growth of Plasmodium falciparum.
    Pattanapanyasat K, Kotipun K, Yongvanitchit K, Hider RC, Kyle DE, Heppner DG, Walsh DS.
    Southeast Asian J Trop Med Public Health; 2001 Mar 15; 32(1):64-9. PubMed ID: 11485097
    [Abstract] [Full Text] [Related]

  • 24. In vivo iron mobilisation evaluation of hydroxypyridinones in 59Fe-ferritin-loaded rat model.
    Liu ZD, Lu SL, Hider RC.
    Biochem Pharmacol; 1999 Mar 01; 57(5):559-66. PubMed ID: 9952320
    [Abstract] [Full Text] [Related]

  • 25. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE, van Acker SA, van der Vijgh WJ, van Asbeck BS, Bast A.
    J Mol Cell Cardiol; 1994 Sep 01; 26(9):1179-85. PubMed ID: 7815460
    [Abstract] [Full Text] [Related]

  • 26. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
    Kalinowski DS, Sharpe PC, Bernhardt PV, Richardson DR.
    J Med Chem; 2008 Jan 24; 51(2):331-44. PubMed ID: 18159922
    [Abstract] [Full Text] [Related]

  • 27. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
    Chaston TB, Richardson DR.
    Am J Hematol; 2003 Jul 24; 73(3):200-10. PubMed ID: 12827659
    [Abstract] [Full Text] [Related]

  • 28. Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity.
    Bernhardt PV, Chin P, Sharpe PC, Wang JY, Richardson DR.
    J Biol Inorg Chem; 2005 Nov 24; 10(7):761-77. PubMed ID: 16193304
    [Abstract] [Full Text] [Related]

  • 29. [Current possibilities in the therapy of iron overload].
    Cermák J.
    Vnitr Lek; 1994 Sep 24; 40(9):605-8. PubMed ID: 7975366
    [Abstract] [Full Text] [Related]

  • 30. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.
    Zhou T, Neubert H, Liu DY, Liu ZD, Ma YM, Kong XL, Luo W, Mark S, Hider RC.
    J Med Chem; 2006 Jul 13; 49(14):4171-82. PubMed ID: 16821777
    [Abstract] [Full Text] [Related]

  • 31. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential.
    Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao G, van der Helm D.
    J Med Chem; 1993 Aug 20; 36(17):2448-58. PubMed ID: 8355246
    [Abstract] [Full Text] [Related]

  • 32. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD, Evans RW, Evans PJ, Hider RC.
    Biochem J; 2008 Jan 15; 409(2):439-47. PubMed ID: 17919118
    [Abstract] [Full Text] [Related]

  • 33. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK, Kalinowski DS, Richardson DR.
    Mol Pharmacol; 2008 Jul 15; 74(1):225-35. PubMed ID: 18424550
    [Abstract] [Full Text] [Related]

  • 34. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance.
    Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA.
    Neurosci Lett; 2006 Oct 09; 406(3):189-93. PubMed ID: 16919875
    [Abstract] [Full Text] [Related]

  • 35. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell.
    Richardson D, Ponka P, Baker E.
    Cancer Res; 1994 Feb 01; 54(3):685-9. PubMed ID: 8306330
    [Abstract] [Full Text] [Related]

  • 36. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
    Hoyes KP, Porter JB.
    Br J Haematol; 1993 Oct 01; 85(2):393-400. PubMed ID: 8280612
    [Abstract] [Full Text] [Related]

  • 37. Iron chelators can protect against oxidative stress through ferryl heme reduction.
    Reeder BJ, Hider RC, Wilson MT.
    Free Radic Biol Med; 2008 Feb 01; 44(3):264-73. PubMed ID: 18215735
    [Abstract] [Full Text] [Related]

  • 38. Synthesis and in vitro trypanocidal activity of some novel iron chelating agents.
    Singh PK, Jones MM, Lane JE, Nesset A, Zimmerman LJ, Ribeiro-Rodrigues R, Richter A, Stenger MR, Carter CE.
    Arzneimittelforschung; 1997 Mar 01; 47(3):311-5. PubMed ID: 9105552
    [Abstract] [Full Text] [Related]

  • 39. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
    Kicic A, Chua AC, Baker E.
    Anticancer Drug Des; 2001 Mar 01; 16(4-5):195-207. PubMed ID: 12049478
    [Abstract] [Full Text] [Related]

  • 40. Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice.
    Porter JB, Morgan J, Hoyes KP, Burke LC, Huehns ER, Hider RC.
    Blood; 1990 Dec 01; 76(11):2389-96. PubMed ID: 2257308
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.